XTL Biopharmaceuticals Makes Bold Bet on Autism Breakthrough with NeuroNOS Acquisition
Transformative deal targets the biological roots of autism, opening a new frontier in disease-modifying therapy. XTL Biopharmaceuticals has taken a ...
Tag: XAIR
NeuroNOS Earns FDA Orphan Drug Designation for Glioblastoma Therapy
BA-101 aims to address urgent unmet needs in one of the deadliest brain cancers NeuroNOS, a subsidiary of Beyond Air ...
